NYSE: $MRK A Major Milestone in Cancer Treatment The landscape of cancer therapy is evolving rapidly, and a recent announcement from Merck and Moderna marks a significant turning point. The companies have officially announced that the Phase 3 INTERPATH-001 trial, investigating their investigational individualized neoantigen therapy (INT), known as mRNA-4157 (telixavastat/intismeran), combined with the immunotherapy…